Real-time enrollment status for this relapsed/refractory locally advanced or metastatic breast cancer and triple negative breast cancer clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:45 PM UTC
| NCT Number | NCT02926690 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer |
| Phase | PHASE1 |
| Target Enrollment | 70 participants |
| Active Locations | 8 sites in the US |
| Sponsor | OncoTherapy Science, Inc. |
| Last Updated on CT.gov | February 25, 2026 (Feb 25, 2026) |
As of October 12, 2026: Clinical trial NCT02926690 is currently recruiting participants. This phase1 study for relapsed/refractory locally advanced or metastatic breast cancer and triple negative breast cancer is actively seeking new participants at 8 locations across the United States. The study is sponsored by OncoTherapy Science, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT02926690 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT02926690 was last updated Feb 25, 2026 (February 25, 2026). HelloStudys verifies this status automatically.